BPC-157 Arginate

The arginine salt form of BPC-157, a synthetic pentadecapeptide derived from a protein found in human gastric juice. The di-L-arginine salt (2 mol arginine per mol peptide) was developed and patented by the University of Zagreb group (WO2014142764A1) specifically for improved gastric stability and oral bioavailability compared to the acetate and free-base forms.

Patent data claims significantly enhanced oral stability at pH 7.40, though no peer-reviewed human pharmacokinetic study has independently verified the comparative bioavailability claims. Standard BPC-157 (acetate salt, typically injected subcutaneously) exists as a separate entry in this database. The arginate form is discussed primarily in the context of oral capsule delivery for gastrointestinal applications.

BPC-157's preclinical dataset spans 100+ animal studies over 30 years showing positive healing effects in tendon, ligament, muscle, bone, GI tract, liver, heart, brain, and spinal cord models. No acute lethal dose (LD1) has been identified. However, human evidence is critically thin: a registered Phase 1 trial (NCT02637284) was cancelled, early Croatian IBD trials were never fully published in major journals, and a 2025 IV safety pilot included only 2 subjects.

Regarding the arginate salt specifically: the WO2014142764A1 patent claims superior gastric stability and oral bioavailability versus the acetate form, but no peer-reviewed study has compared the two salt forms in any species. The '7-fold oral bioavailability' claim originates from patent documents and vendor marketing only. The arginate form distinction exists at the patent and commercial level, not in the published scientific literature.